678-636-3060
Sales@mettest.net
CLINICAL TRIALS
We are based out of Atlanta and have a presence in over 50 clinical sites all over the country. We have tested over 200,000 patients since inception in 2003 and currently test about 1200 patients a month. Our operation is primarily focused on real world clinical testing but our cardiopulmonary exercise testing (CPET) platform has the ability to participate in research trials and has been designed as such.
We are present in primary care & cardiology clinics along with a couple of hospitals. Our national objective is to improve population risk management of at-risk organizations by reducing heart-disease related costs with enhanced outpatient management and to track these populations with a centralized database.
The MET-TEST Healthcare Technology as a standardized platform to carry out clinical trials for pharmaceutical and medical device companies looking to collect efficacy data for treatment of ischemic heart disease, heart failure, valve procedures, pulmonary ventilation and pulmonary circulation abnormalities. All systems are centrally monitored for calibration and proper function with multi-site test data stored in one database.
- Strategic advice regarding product impact and practicality
- Services utilization
- Trial design
- Site identification and enrollment
- Data collection and management
- Publication of results through our network of respected academic centers of excellence in the field of cardiopulmonary exercise testing
Our biggest value is in phase III and phase IV post-approval trials. Contact Us form for more information.
List of Services
-
EMORY UNIVERSITYList Item 1
Gilead funded a small trial to study the effects of ranolazine in 50 women with coronary disease and angina using peak VO2 as the primary end point. The PI decided to use our systems instead of Emory's as he thought we did higher quality work. The study took 2.5 years and recently concluded. We saw mixed results and the findings will be published in near future. I am working with a Women's Heart Disease specialist at Emory to study the diagnostic value of CPET to detect small vessel disease in women. She is submitting an NIH grant and is in the works. The head of the cardiac cath lab sends all his patients out of Emory to our corporate location for CPET testing.
-
CV THERAPEUTICS (CVT)List Item 2
We performed a small placebo controlled cross-over study about 10 years ago for this company's drug ranolazine and found the drug worked better in heart failure patients than angina patients. The company made a fatal error in developing the drug for angina. CVT got bought by Gilead shortly prior to our finishing the data collection. Gilead decided not to fund anymore large clinical trials for the agent.
-
STEM CELL THERAPYList Item 3
We are actively engaged to help recruit and serially test heart failure patients for a company involved in stem cell therapy. They intend to build a registry of 200+ patients. This is still in the planning phases with a lot of interest in our platform.
